|
195 Companies |
|
327 Products |
|
327 Products |
|
167 Mechanisms of Action |
|
13 Trials |
|
3266 News |
|
| «12...3233343536373839404142...6768» |
- Trial primary completion date: Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jul 4, 2014
P1, N=18, Recruiting, Sponsor: OHSU Knight Cancer Institute
Trial primary completion date: Dec 2014 --> Apr 2015
- Trial primary completion date: A Prospective Controlled Study on Treatment of Giant Cavernous Hemangiomas of the Liver (clinicaltrials.gov) - Jul 2, 2014
P=N/A, N=140, Completed, Sponsor: Southwest Hospital, China
Trial primary completion date: Dec 2014 --> Apr 2015 Trial primary completion date: Mar 2013 --> Oct 2013
- Trial completion, Trial primary completion date: A Prospective Controlled Study on Treatment of Giant Cavernous Hemangiomas of the Liver (clinicaltrials.gov) - Jul 2, 2014
P=N/A, N=140, Completed, Sponsor: Southwest Hospital, China
Trial primary completion date: Mar 2013 --> Oct 2013 Recruiting --> Completed | Trial primary completion date: Mar 2013 --> Oct 2013
- TevaGrastim (filgrastim biosimilar) / Nippon Kayaku, Teva, Mozobil (plerixafor) / Sanofi
Phase classification, Combination therapy, Head-to-Head: Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jul 1, 2014
P2, N=100, Not yet recruiting, Sponsor: Washington University School of Medicine
Recruiting --> Completed | Trial primary completion date: Mar 2013 --> Oct 2013 Phase classification: P=N/A --> P2
- Zolinza (vorinostat) / Merck (MSD)
Trial primary completion date, Combination therapy: Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM) (clinicaltrials.gov) - Jul 1, 2014
P1/2, N=30, Recruiting, Sponsor: University Hospital Freiburg
Phase classification: P=N/A --> P2 Trial primary completion date: Aug 2013 --> Jul 2016
- NovoSeven (eptacog alfa) / Novo Nordisk
Trial primary completion date: Safety and Efficacy of Activated Recombinant Human Factor VII in Patients Undergoing Orthotopic Liver Transplantation (clinicaltrials.gov) - Jun 27, 2014
P2, N=208, Completed, Sponsor: Novo Nordisk A/S
Trial primary completion date: Aug 2013 --> Jul 2016 Trial primary completion date: Aug 2002 --> Sep 2003
- Clinical: Reproductive Health in Men and Women With Vasculitis (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=467, Completed, Sponsor: University of South Florida
- Campath (alemtuzumab) / Sanofi
Enrollment change: Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer (clinicaltrials.gov) - Jun 27, 2014
P2, N=11, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Aug 2002 --> Sep 2003 N=100 --> 11
- Phase classification, Post-transplantation: Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Jun 27, 2014
P0, N=20, Recruiting, Sponsor: Washington University School of Medicine
N=100 --> 11 Phase classification: P=N/A --> P0
- Enrollment open, Phase classification, Post-transplantation: Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Jun 27, 2014
P0, N=20, Recruiting, Sponsor: Washington University School of Medicine
Phase classification: P=N/A --> P0 Not yet recruiting --> Recruiting | Phase classification: PN/A --> P0
- |||| Inrebic (fedratinib) / BMS
Trial completion: Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia (clinicaltrials.gov) - Jun 27, 2014
P2, N=81, Completed, Sponsor: Sanofi
Not yet recruiting --> Recruiting | Phase classification: PN/A --> P0 Active, not recruiting --> Completed
- lenalidomide / Generic mfg.
Trial primary completion date: Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure Patients (clinicaltrials.gov) - Jun 26, 2014
P2, N=32, Recruiting, Sponsor: University Health Network, Toronto
Active, not recruiting --> Completed Trial primary completion date: Mar 2012 --> Mar 2016
- Uplizna (inebilizumab-cdon) / Mitsubishi Tanabe, Amgen
Enrollment open, Combination therapy: Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma (clinicaltrials.gov) - Jun 26, 2014
P0, N=15, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: Mar 2012 --> Mar 2016 Not yet recruiting --> Recruiting
- Fibryga (fibrinogen concentrate (human)) / Octapharma
Trial primary completion date: Pharmacokinetic, Efficacy, and Safety Study of Octafibrin Compared to Haemocomplettan/Riastap (clinicaltrials.gov) - Jun 24, 2014
P2, N=18, Recruiting, Sponsor: Octapharma
Not yet recruiting --> Recruiting Trial primary completion date: Mar 2014 --> Jul 2014
- ||| alisertib (MLN8237) / Puma
Enrollment closed: Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jun 24, 2014
P1/2, N=69, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Mar 2014 --> Jul 2014 Recruiting --> Active, not recruiting
- | Jakafi (ruxolitinib) / Novartis, Incyte
Trial completion, P2 data: Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) (clinicaltrials.gov) - Jun 22, 2014
P4, N=48, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma, Rituxan (rituximab) / Roche
New P1 trial, Combination therapy: CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jun 22, 2014
P1, N=14, Not yet recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
- methoxyamine (TRC102) / Tracon Pharma
Enrollment closed: Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies (clinicaltrials.gov) - Jun 22, 2014
P1, N=30, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Sylvant (siltuximab) / Jazz
Trial completion: A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma (clinicaltrials.gov) - Jun 22, 2014
P1, N=30, Completed, Sponsor: Janssen Research & Development, LLC
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Uplizna (inebilizumab-cdon) / Mitsubishi Tanabe, Amgen
Enrollment open, Trial initiation date, Combination therapy: Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma (clinicaltrials.gov) - Jun 22, 2014
P0, N=15, Not yet recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed Initiation date: Aug 2013 --> Aug 2014 | Not yet recruiting --> Recruiting
- |||| lenalidomide / Generic mfg.
Trial primary completion date: Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma (clinicaltrials.gov) - Jun 19, 2014
P3, N=194, Recruiting, Sponsor: Gesellschaft fur Medizinische Innovation
Initiation date: Aug 2013 --> Aug 2014 | Not yet recruiting --> Recruiting Trial primary completion date: Apr 2013 --> Jun 2018
- fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg.
Trial primary completion date: Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer (clinicaltrials.gov) - Jun 19, 2014
P2, N=100, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: Apr 2013 --> Jun 2018 Trial primary completion date: Dec 2014 --> Dec 2015
- bortezomib / Generic mfg., lenalidomide / Generic mfg.
Enrollment change: Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone (clinicaltrials.gov) - Jun 19, 2014
P3, N=47, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2014 --> Dec 2015 N=392 --> 47
- marizomib (NPI-0052) / Triphase Accelerator Corporation, BMS
Clinical: Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov) - Jun 19, 2014
P1, N=36, Recruiting, Sponsor: Triphase Research and Development I Corporation
N=392 --> 47 Not yet recruiting --> Recruiting
- Biomarker: Biomarkers in Vascular Ehlers-Danlos Syndrome (clinicaltrials.gov) - Jun 18, 2014
P=N/A, N=200, Recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
- Clinical: PROPRIO-HE: Bilateral Deficit Phenomenon in Patients With Haemophilic Arthropathy (clinicaltrials.gov) - Jun 18, 2014
P=N/A, N=30, Not yet recruiting, Sponsor: Universidad Católica San Antonio de Murcia
- fludarabine IV / Generic mfg., busulfan / Generic mfg.
Trial primary completion date: Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease (clinicaltrials.gov) - Jun 18, 2014
P2, N=70, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2013 --> Dec 2015
- everolimus / Generic mfg.
Trial primary completion date: Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia (clinicaltrials.gov) - Jun 17, 2014
P2, N=33, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Dec 2013 --> Dec 2015 Trial primary completion date: Dec 2011 --> Jul 2014
- Trial initiation date: F7CONDEF: Treatment of Congenital Factor VII Deficiency (clinicaltrials.gov) - Jun 17, 2014
P=N/A, N=163, Completed, Sponsor: Novo Nordisk A/S
Trial primary completion date: Dec 2011 --> Jul 2014 Initiation date: Mar 2004 --> Oct 2005
- | anagrelide CR (GALE-401) / SELLAS Life Sciences
Enrollment open: A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders (clinicaltrials.gov) - Jun 17, 2014
P2, N=20, Recruiting, Sponsor: Galena Biopharma, Inc.
Initiation date: Mar 2004 --> Oct 2005 Not yet recruiting --> Recruiting
- ||||| vatreptacog alfa (NN 1731) / Novo Nordisk
Trial initiation date: Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors (clinicaltrials.gov) - Jun 15, 2014
P3, N=72, Completed, Sponsor: Novo Nordisk
Not yet recruiting --> Recruiting Initiation date: Jul 2011 --> Jul 2012
- Onureg (azacitidine oral) / BMS
Trial primary completion date: Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms (clinicaltrials.gov) - Jun 13, 2014
P1, N=30, Suspended, Sponsor: Celgene Corporation
Initiation date: Jul 2011 --> Jul 2012 Trial primary completion date: Dec 2014 --> Jan 2016
- Empliciti (elotuzumab) / AbbVie, BMS
Trial primary completion date, Combination therapy: Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function (clinicaltrials.gov) - Jun 13, 2014
P1, N=26, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Dec 2014 --> Jan 2016 Trial primary completion date: Sep 2014 --> Mar 2014
- melphalan / Generic mfg., pomalidomide / Generic mfg.
Clinical: Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Jun 13, 2014
P2, N=48, Active, not recruiting, Sponsor: Yale University
Trial primary completion date: Sep 2014 --> Mar 2014 Trial primary completion date: May 2014 --> Oct 2014
- dexamethasone / Generic mfg., lenalidomide / Generic mfg.
Trial primary completion date: Lenalidomide (Revlimid (clinicaltrials.gov) - Jun 13, 2014
P2, N=62, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Trial primary completion date: May 2014 --> Oct 2014 Trial primary completion date: Dec 2014 --> Dec 2015
- Onureg (azacitidine oral) / BMS
Enrollment change: Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms (clinicaltrials.gov) - Jun 13, 2014
P1, N=30, Suspended, Sponsor: Celgene Corporation
Trial primary completion date: Dec 2014 --> Dec 2015 N=18 --> 30
- Empliciti (elotuzumab) / AbbVie, BMS
Enrollment open, Trial primary completion date, Combination therapy: Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function (clinicaltrials.gov) - Jun 13, 2014
P1, N=26, Recruiting, Sponsor: Bristol-Myers Squibb
N=18 --> 30 Active, not recruiting --> Recruiting | Trial primary completion date: Sep 2014 --> Mar 2014
- || ulocuplumab (BMS-936564) / BMS
Enrollment closed, Combination therapy: Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Jun 13, 2014
P1, N=64, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Recruiting | Trial primary completion date: Sep 2014 --> Mar 2014 Recruiting --> Active, not recruiting
- | melphalan / Generic mfg., pomalidomide / Generic mfg.
Clinical: Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Jun 13, 2014
P2, N=48, Active, not recruiting, Sponsor: Yale University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: May 2014 --> Oct 2014
- Phase classification: Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Jun 12, 2014
P2, N=18, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial primary completion date: May 2014 --> Oct 2014 Phase classification: P1 --> P2
- ||||| I.V.-Globulin SN (human immune globulin intravenous) / Green Cross
Trial initiation date: An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune Thrombocytopenia (clinicaltrials.gov) - Jun 12, 2014
P3, N=70, Recruiting, Sponsor: Green Cross Corporation
Phase classification: P1 --> P2 Initiation date: Mar 2014 --> Jun 2014
- |||||| I.V.-Globulin SN (human immune globulin intravenous) / Green Cross
Enrollment open: An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune Thrombocytopenia (clinicaltrials.gov) - Jun 12, 2014
P3, N=70, Recruiting, Sponsor: Green Cross Corporation
Initiation date: Mar 2014 --> Jun 2014 Not yet recruiting --> Recruiting
- ||| Darzalex (daratumumab) / J&J
Immunomodulating: Sirius: An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD (clinicaltrials.gov) - Jun 12, 2014
P2, N=126, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Koselugo (selumetinib) / Merck (MSD), AstraZeneca
Trial primary completion date: AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma (clinicaltrials.gov) - Jun 8, 2014
P2, N=36, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2015 --> Mar 2012
- cyclophosphamide / Generic mfg.
Trial primary completion date: OCTET-CY: Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation (clinicaltrials.gov) - Jun 7, 2014
P2, N=11, Completed, Sponsor: University of Cologne
Trial primary completion date: Mar 2015 --> Mar 2012 Trial primary completion date: Dec 2011 --> Dec 2013
- cyclophosphamide / Generic mfg.
Trial completion: OCTET-CY: Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation (clinicaltrials.gov) - Jun 7, 2014
P2, N=11, Completed, Sponsor: University of Cologne
Trial primary completion date: Dec 2011 --> Dec 2013 Recruiting --> Completed
- || bortezomib / Generic mfg., dexamethasone / Generic mfg., lenalidomide / Generic mfg.
Trial primary completion date, Combination therapy: Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov) - Jun 5, 2014
P2, N=65, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Completed Trial primary completion date: Jul 2012 --> Oct 2012
- Trial termination, Head-to-Head: Hemophilia Adult Prophylaxis Study: Factor VIII in Severe Hemophilia A (clinicaltrials.gov) - Jun 4, 2014
P3, N=4, Terminated, Sponsor: University of Pittsburgh
Trial primary completion date: Jul 2012 --> Oct 2012 Recruiting --> Terminated; study was non-feasible per DSMB
- Enrollment change, Head-to-Head: Hemophilia Adult Prophylaxis Study: Factor VIII in Severe Hemophilia A (clinicaltrials.gov) - Jun 4, 2014
P3, N=4, Terminated, Sponsor: University of Pittsburgh
Recruiting --> Terminated; study was non-feasible per DSMB N=20 --> 4
- Trial withdrawal: Fresh-Frozen Plasma Infusions to Reduce Risk of Bleeding Related to Invasive Procedures (clinicaltrials.gov) - Jun 4, 2014
P3, N=0, Withdrawn, Sponsor: Massachusetts General Hospital
N=20 --> 4 Terminated --> Withdrawn